Cost implications of new treatments for advanced colorectal cancer

Yu Ning Wong, Neal J. Meropol, William Speier, Daniel Sargent, Richard M. Goldberg, J. Robert Beck

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

BACKGROUND: Since 1996, 6 new drugs have been introduced for the treatment of metastatic colorectal cancer. Although they are promising, these drugs frequently are given in the palliative and are much more expensive than older treatments. The objective of the current study was to measure the cost implications of treatment with sequential regimens that include chemotherapy and/or monoclonal antibodies. METHODS: A Markov model was used to evaluate a hypothetical cohort of 1000 patients with newly diagnosed, metastatic colorectal cancer. Patients supposedly received up to 3 lines of treatment before supportive care and subsequent death. Data were obtained from published, multicenter phase 2 and randomized phase 3 clinical trials. Sensitivity analyses were conducted on the efficacy, toxicity, and cost. RESULTS: Using drug costs alone, treatment that included new chemotherapeutic agents increased survival at an incremental cost-effectiveness ratio (ICER) of $100,000 per discounted life-year (DLY). The addition of monoclonal antibodies improved survival at an ICER of >$170,000 per DLY. The results were most sensitive to changes in the initial regimen. Even with significant improvements in clinical characteristics (efficacy and toxicity), treatment with the most effective regimens still had very high ICERs. CONCLUSIONS: Treatment of metastatic colorectal cancer with the most effective regimens came at very high incremental costs. The authors concluded that cost-effectiveness analyses should be a routine component of the drug-development process, so that physicians and patients are informed appropriately regarding the value of new innovations.

Original languageEnglish (US)
Pages (from-to)2081-2091
Number of pages11
JournalCancer
Volume115
Issue number10
DOIs
StatePublished - May 15 2009

Fingerprint

Colorectal Neoplasms
Costs and Cost Analysis
Cost-Benefit Analysis
Therapeutics
Monoclonal Antibodies
Pharmaceutical Preparations
Phase III Clinical Trials
Drug Costs
Survival
Health Care Costs
Randomized Controlled Trials
Physicians
Drug Therapy

Keywords

  • Cost-effectiveness
  • Incremental cost-effectiveness ratio
  • Metastatic colorectal cancer
  • Monoclonal antibodies
  • Monte Carlo simulation
  • Palliative chemotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Wong, Y. N., Meropol, N. J., Speier, W., Sargent, D., Goldberg, R. M., & Beck, J. R. (2009). Cost implications of new treatments for advanced colorectal cancer. Cancer, 115(10), 2081-2091. https://doi.org/10.1002/cncr.24246

Cost implications of new treatments for advanced colorectal cancer. / Wong, Yu Ning; Meropol, Neal J.; Speier, William; Sargent, Daniel; Goldberg, Richard M.; Beck, J. Robert.

In: Cancer, Vol. 115, No. 10, 15.05.2009, p. 2081-2091.

Research output: Contribution to journalArticle

Wong, YN, Meropol, NJ, Speier, W, Sargent, D, Goldberg, RM & Beck, JR 2009, 'Cost implications of new treatments for advanced colorectal cancer', Cancer, vol. 115, no. 10, pp. 2081-2091. https://doi.org/10.1002/cncr.24246
Wong YN, Meropol NJ, Speier W, Sargent D, Goldberg RM, Beck JR. Cost implications of new treatments for advanced colorectal cancer. Cancer. 2009 May 15;115(10):2081-2091. https://doi.org/10.1002/cncr.24246
Wong, Yu Ning ; Meropol, Neal J. ; Speier, William ; Sargent, Daniel ; Goldberg, Richard M. ; Beck, J. Robert. / Cost implications of new treatments for advanced colorectal cancer. In: Cancer. 2009 ; Vol. 115, No. 10. pp. 2081-2091.
@article{1ae0bc6c5fa54e1991a22667a4aadde7,
title = "Cost implications of new treatments for advanced colorectal cancer",
abstract = "BACKGROUND: Since 1996, 6 new drugs have been introduced for the treatment of metastatic colorectal cancer. Although they are promising, these drugs frequently are given in the palliative and are much more expensive than older treatments. The objective of the current study was to measure the cost implications of treatment with sequential regimens that include chemotherapy and/or monoclonal antibodies. METHODS: A Markov model was used to evaluate a hypothetical cohort of 1000 patients with newly diagnosed, metastatic colorectal cancer. Patients supposedly received up to 3 lines of treatment before supportive care and subsequent death. Data were obtained from published, multicenter phase 2 and randomized phase 3 clinical trials. Sensitivity analyses were conducted on the efficacy, toxicity, and cost. RESULTS: Using drug costs alone, treatment that included new chemotherapeutic agents increased survival at an incremental cost-effectiveness ratio (ICER) of $100,000 per discounted life-year (DLY). The addition of monoclonal antibodies improved survival at an ICER of >$170,000 per DLY. The results were most sensitive to changes in the initial regimen. Even with significant improvements in clinical characteristics (efficacy and toxicity), treatment with the most effective regimens still had very high ICERs. CONCLUSIONS: Treatment of metastatic colorectal cancer with the most effective regimens came at very high incremental costs. The authors concluded that cost-effectiveness analyses should be a routine component of the drug-development process, so that physicians and patients are informed appropriately regarding the value of new innovations.",
keywords = "Cost-effectiveness, Incremental cost-effectiveness ratio, Metastatic colorectal cancer, Monoclonal antibodies, Monte Carlo simulation, Palliative chemotherapy",
author = "Wong, {Yu Ning} and Meropol, {Neal J.} and William Speier and Daniel Sargent and Goldberg, {Richard M.} and Beck, {J. Robert}",
year = "2009",
month = "5",
day = "15",
doi = "10.1002/cncr.24246",
language = "English (US)",
volume = "115",
pages = "2081--2091",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Cost implications of new treatments for advanced colorectal cancer

AU - Wong, Yu Ning

AU - Meropol, Neal J.

AU - Speier, William

AU - Sargent, Daniel

AU - Goldberg, Richard M.

AU - Beck, J. Robert

PY - 2009/5/15

Y1 - 2009/5/15

N2 - BACKGROUND: Since 1996, 6 new drugs have been introduced for the treatment of metastatic colorectal cancer. Although they are promising, these drugs frequently are given in the palliative and are much more expensive than older treatments. The objective of the current study was to measure the cost implications of treatment with sequential regimens that include chemotherapy and/or monoclonal antibodies. METHODS: A Markov model was used to evaluate a hypothetical cohort of 1000 patients with newly diagnosed, metastatic colorectal cancer. Patients supposedly received up to 3 lines of treatment before supportive care and subsequent death. Data were obtained from published, multicenter phase 2 and randomized phase 3 clinical trials. Sensitivity analyses were conducted on the efficacy, toxicity, and cost. RESULTS: Using drug costs alone, treatment that included new chemotherapeutic agents increased survival at an incremental cost-effectiveness ratio (ICER) of $100,000 per discounted life-year (DLY). The addition of monoclonal antibodies improved survival at an ICER of >$170,000 per DLY. The results were most sensitive to changes in the initial regimen. Even with significant improvements in clinical characteristics (efficacy and toxicity), treatment with the most effective regimens still had very high ICERs. CONCLUSIONS: Treatment of metastatic colorectal cancer with the most effective regimens came at very high incremental costs. The authors concluded that cost-effectiveness analyses should be a routine component of the drug-development process, so that physicians and patients are informed appropriately regarding the value of new innovations.

AB - BACKGROUND: Since 1996, 6 new drugs have been introduced for the treatment of metastatic colorectal cancer. Although they are promising, these drugs frequently are given in the palliative and are much more expensive than older treatments. The objective of the current study was to measure the cost implications of treatment with sequential regimens that include chemotherapy and/or monoclonal antibodies. METHODS: A Markov model was used to evaluate a hypothetical cohort of 1000 patients with newly diagnosed, metastatic colorectal cancer. Patients supposedly received up to 3 lines of treatment before supportive care and subsequent death. Data were obtained from published, multicenter phase 2 and randomized phase 3 clinical trials. Sensitivity analyses were conducted on the efficacy, toxicity, and cost. RESULTS: Using drug costs alone, treatment that included new chemotherapeutic agents increased survival at an incremental cost-effectiveness ratio (ICER) of $100,000 per discounted life-year (DLY). The addition of monoclonal antibodies improved survival at an ICER of >$170,000 per DLY. The results were most sensitive to changes in the initial regimen. Even with significant improvements in clinical characteristics (efficacy and toxicity), treatment with the most effective regimens still had very high ICERs. CONCLUSIONS: Treatment of metastatic colorectal cancer with the most effective regimens came at very high incremental costs. The authors concluded that cost-effectiveness analyses should be a routine component of the drug-development process, so that physicians and patients are informed appropriately regarding the value of new innovations.

KW - Cost-effectiveness

KW - Incremental cost-effectiveness ratio

KW - Metastatic colorectal cancer

KW - Monoclonal antibodies

KW - Monte Carlo simulation

KW - Palliative chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=65649098736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65649098736&partnerID=8YFLogxK

U2 - 10.1002/cncr.24246

DO - 10.1002/cncr.24246

M3 - Article

C2 - 19309745

AN - SCOPUS:65649098736

VL - 115

SP - 2081

EP - 2091

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 10

ER -